Procedural safety of a fully implantable pump for delivery of intravenous prostanoids in severe pulmonary hypertension: A two-center observational study Source: International Congress 2016 – Pulmonary hypertension: the clinic I Year: 2016
Combination therapy in severe pulmonary hypertension with bosentan and treprostinil: successful switch from subcutaneous to intravenous application Source: Eur Respir J 2006; 28: Suppl. 50, 384s Year: 2006
Safety and pharmacokinetics study of a single ascending dose of C16TR for inhalation (INS1009) Source: International Congress 2016 – Pulmonary hypertension: the clinic II Year: 2016
Complications of a permanently implanted port system for continuous epoprostenol treatment in pulmonary hypertension Source: Eur Respir J 2002; 20: Suppl. 38, 597s Year: 2002
Long-term safety of a new formulation of epoprostenol in pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment Year: 2013
EPITOME-4, a phase 3b study evaluating a new formulation of epoprostenol sodium in pulmonary arterial hypertension following switch from Flolan® Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment Year: 2013
Initial dual oral combination therapy for pulmonary arterial hypertension (PAH) in daily practice Source: International Congress 2015 – Pulmonary hypertension: management Year: 2015
Low dose intravenous iloprost therapy in idiopathic pulmonary arterial hypertension Source: Eur Respir J 2006; 28: Suppl. 50, 426s Year: 2006
Intravenous prostacyclin for pulmonary hypertension: Patient’s perspective on complications Source: International Congress 2016 – Pulmonary hypertension and pulmonary embolism: from the bench to the bedside Year: 2016
Single dose pharmacokinetics of C16TR for Inhalation (INS1009) vs treprostinil inhalation solution Source: International Congress 2016 – Pulmonary hypertension: the clinic II Year: 2016
Safety and long-term efficacy of transition from sildenafil to tadalafil due to side effects in patients with pulmonary arterial hypertension Source: International Congress 2014 – Modern approach and old dilemmas in lung diseases Year: 2014
Broviac catheter complications of intravenous epoprostenol therapy in patients with pulmonary arterial hypertension Source: Eur Respir J 2004; 24: Suppl. 48, 636s Year: 2004
Safety and tolerability of rapid dose-titration of subcutaneous (SC) treprostinil in pulmonary arterial hypertension (PAH) Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights Year: 2015
Prolonged activity of inhaled treprostinil prodrug nanoparticles in a rat model of pulmonary arterial hypertension Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014
Experience with subcutaneous treprostinil in children with pulmonary arterial hypertension Source: International Congress 2017 – NICU/ PICU: evaluating short- and long-term ventilatory management Year: 2017
Risk assessment and prognosis in patients with pulmonary arterial hypertension receiving intravenous treprostinil Source: International Congress 2019 – Endpoints and risk assessment of pulmonary arterial hypertension Year: 2019
Transitioning sildenafil to taladafil in PAH patients is safe Source: International Congress 2015 – Pulmonary hypertension: management Year: 2015
Use of iloprost in early pregancy in pulmonary hypertension Source: Annual Congress 2004 - Pulmonary hypertension Year: 2004
Long-term continuous subcutaneous treprostinil therapy for pulmonary arterial hypertension (PAH) Source: Eur Respir J 2003; 22: Suppl. 45, 461s Year: 2003
Does I.V. continuous antibiotic treatment increase the risk of totally implantable vascular devices complications in CF? Source: Eur Respir J 2005; 26: Suppl. 49, 620s Year: 2005